Is exercise a therapeutic tool for improvement of cardiovascular risk factors in adolescents with type 1 diabetes mellitus? A randomised controlled trial

<p>Abstract</p> <p>Background</p> <p>Type 1 diabetes mellitus (T1DM) is associated with a high risk for early atherosclerotic complications especially risk of coronary heart disease.</p> <p>Objective</p> <p>To evaluate the impact of six months exercise prgram on glycemic control, plasma lipids values, blood pressure, severity and frequency of hypoglycemia, anthropometric measurements and insulin dose in a sample of adolescents with T1DM.</p> <p>Research design and methods</p> <p>A total of 196 type 1 diabetic patients participated in the study. They were classified into three groups: Group (A) did not join the exercise program(n = 48), group (B) attended the exercise sessions once/week (n = 75), group (C) attended the exercise sessions three times/week (n = 73). Studied parameters were evaluated before and six months after exercise programe.</p> <p>Results</p> <p>Exercise improved glycemic control by reducing HbA1c values in exercise groups (P = 0.03, P = 0.01 respectively) and no change in those who were not physically active (P = 0.2). Higher levels of HbA1c were associated with higher levels of cholesterol, LDL-c, and triglycerides (P = 0.000 each). In both groups, B and C, frequent exercise improved dyslipidemia and reduced insulin requirements significantly (P = 0.00 both), as well as a reduction in BMI (P = 0.05, P = 0.00 respectively) and waist circumference(P = 0.02, P = 0.00 respectively). The frequency of hypoglycemic attacks were not statistically different between the control group and both intervention groups (4.7 ± 3.56 and 4.82 ± 4.23, P = 0.888 respectively). Reduction of blood pressure was statistically insignificant apart from the diastolic blood presure in group C (P = 0.04).</p> <p>Conclusion</p> <p>Exercise is an indispensable component in the medical treatment of patients with T1DM as it improves glycemic control and decreases cardiovascular risk factors among them.</p

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Efeitos do treinamento de resistência na força muscular e níveis de fadiga em pacientes com câncer de mama Los efectos de los ejercicios de resistencia sobre varios músculos y niveles de fatiga en pacientes con cáncer de mama The effects of resistance training on muscular strength and fatigue levels in breast cancer patients

Os efeitos de programas generalizados de atividade física no combate ao câncer e aos efeitos colaterais de seu tratamento têm sido amplamente relatados na literatura. O objetivo do presente estudo foi o de examinar os efeitos de um programa de prescrição de exercício físico individualizado, com ênfase no treinamento resistido, na força muscular e nos níveis de fadiga em pacientes portadoras de câncer de mama em tratamento. Vinte mulheres foram divididas aleatoriamente em dois grupos, sendo um experimental (57,5 ± 23,0 anos) e um controle (56,6 ± 16,0 anos). O grupo experimental exercitou-se, após a cirurgia, durante 60 minutos, de forma moderada, duas vezes por semana, durante 21 semanas. A força muscular total foi avaliada antes e após o tratamento e os níveis de fadiga foram avaliados em três momentos durante o treinamento. Foram encontradas diferenças significativas na força muscular total entre os grupos após o treinamento (p = 0,025). Os níveis de fadiga diminuíram significativamente entre os grupos após a primeira (p = 0,001) e a segunda (p = 0,005) intervenção e ao final do tratamento (p = 0,001). Os resultados deste estudo sugerem que os exercícios resistidos devem ser incluídos na prescrição de exercícios no combate da fadiga e na melhoria da força muscular em mulheres com câncer de mama, submetidas a tratamento.<br>Los efectos de programas generalizados de actividad física de combate al cáncer y los efectos colaterales de su tratamiento vienen siendo bastante estudiados. El objetivo del presente estudio ha sido el de examinar los efectos de un programa prescrito de ejercicio físico individual, con énfasis en el entrenamiento resistido, en la fuerza muscular y en los niveles de fatiga en pacientes portadoras de cáncer de mama en tratamiento. Veinte mujeres fueron divididas aleatoriamente en dos grupos, siendo uno de ellos el experimental (57,5 ± 23,0 años) y el otro de control (56,6 ± 16,0 años). El grupo experimental se ejercitó después de una cirugía durante 60 minutos, de forma moderada, dos veces por semana, durante 21 semanas. La fuerza muscular total fue evaluada antes y después del tratamiento y los niveles de fatiga fueron evaluados en cuatro momentos durante los ejercicios. Fueron encontradas diferencias significativas en la fuerza muscular total entre los grupos después de los ejercicios (p = 0,025). Los niveles de fatiga disminuyeron significativamente entre los grupos después de la primera (p = 0,001) y la segunda (p = 0,005) intervención y al final del tratamiento (p = 0,001). Los resultados de este estudio sugieren que los ejercicios resistidos deben ser incluidos en la prescripción de ejercicios de combate a la fatiga y en la mejoría de la fuerza muscular en mujeres con cáncer de mama sometidas a tratamiento.<br>The effects of generalized exercise programs to combat cancer and cancer treatment-related side effects have been extensively reported in the literature. The purpose of this study was to examine the effects of an individualized exercise program with emphasis on resistance exercise, changes in muscular strength and fatigue in breast cancer female patients under treatment. Twenty subjects were randomly divided in two groups: an experimental (57.5 ± 23.0 years) and a control (56.6 ± 16.0 years) group. A twenty-one week intervention involving pre- and post-functional assessments, prescriptive exercise, and three moments of fatigue measures was used. The experimental group exercised at a low to moderate-intensity for sixty minutes two days a week beginning after surgery. Significant differences in overall muscular strength were observed between groups post-intervention (p = 0.025). Fatigue was also significantly different between groups at treatment one (p = 0.001), treatment two (p = 0.005) and post-intervention (p = 0.001). The results of this study suggest that an emphasis on resistance training should be utilized to combat fatigue and to increase muscular strength in breast cancer patients undergoing treatment